CEACAM5 and carcinoma: The previously described [16, 22–25, 31, 32, 52–56, 68–71] wide level expression of CEA, brachyury, and MUC1 in a range of human carcinomas, along with their diverse activity in human tumors, renders the simultaneous targeting of these three TAAs of potential clinical benefit.